SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of respiratory and urologic disorders, as well as ...
Afferent is developing molecules that selectively block P2X3, a purinergic receptor, which plays a key role in the sensitization of these nerves. Afferent’s lead molecule, AF-219, is a first-in-class ...
Afferent Pharmaceuticals today announced publication of results from a Phase 2 clinical trial demonstrating that the company's novel drug candidate, AF-219, reduced daytime cough frequency by 75% ...
Merck & Co. Inc. MRK announced its intention to acquire privately held biotech company Afferent Pharmaceuticals in a deal which could see the company paying up to $1.25 billion. Deal to Add Chronic ...
Merck & Co. (MRK) might be slipping in Friday’s session, but the company is definitely making waves in its industry with its most recent acquisition agreement. Merck and Afferent Pharmaceuticals ...
- Neuroscience Industry Veteran to Lead Development of Chronic Pain Treatments; Technology Targets Novel Biological Pathway - PALO ALTO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a ...
Afferent Also Appoints Kathleen Sereda Glaub to the Company's Board of Directors SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals today announced that Michael M. Kitt, M.D., has been named ...
Merck & Co has agreed to buy Afferent Pharmaceuticals, and its lead respiratory drug, in a deal worth up to $1.25 billion. The acquisition comes at a time when Merck’s revenues are beginning to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results